Goldman Sachs
GLUE icon

Goldman Sachs’s Monte Rosa Therapeutics GLUE Stock Holding History

Goldman Sachs’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2M Sell
998,253
-3,274
-0.3% -$61.9K ﹤0.01% 2453
2026
Q1 		$16.5M Buy
1,001,527
+705,649
+238% +$13.5M ﹤0.01% 2625
2025
Q4 		$4.64M Buy
295,878
+194,734
+193% +$2.62M ﹤0.01% 3820
2025
Q3 		$749K Sell
101,144
-247,064
-71% -$1.31M ﹤0.01% 5242
2025
Q2 		$1.57M Sell
348,208
-7,904
-2% -$35.3K ﹤0.01% 4363
2025
Q1 		$1.65M Buy
356,112
+196,238
+123% +$1.2M ﹤0.01% 4313
2024
Q4 		$1.11M Sell
159,874
-18,731
-10% -$141K ﹤0.01% 4750
2024
Q3 		$947K Buy
178,605
+86,256
+93% +$435K ﹤0.01% 4669
2024
Q2 		$345K Buy
92,349
+76,585
+486% +$390K ﹤0.01% 5021
2024
Q1 		$111K Sell
15,764
-21,414
-58% -$127K ﹤0.01% 5233
2023
Q4 		$210K Sell
37,178
-17,032
-31% -$66.8K ﹤0.01% 5133
2023
Q3 		$260K Buy
54,210
+8,874
+20% +$57.1K ﹤0.01% 4954
2023
Q2 		$311K Buy
45,336
+13,103
+41% +$84.7K ﹤0.01% 4990
2023
Q1 		$251K Sell
32,233
-11,729
-27% -$81.6K ﹤0.01% 5197
2022
Q4 		$335K Buy
43,962
+10,668
+32% +$88.9K ﹤0.01% 5088
2022
Q3 		$272K Sell
33,294
-6,822
-17% -$62.7K ﹤0.01% 5342
2022
Q2 		$388K Sell
40,116
-9,701
-19% -$97.5K ﹤0.01% 5260
2022
Q1 		$698K Buy
49,817
+15,071
+43% +$209K ﹤0.01% 5111
2021
Q4 		$710K Buy
34,746
+15,627
+82% +$327K ﹤0.01% 5110
2021
Q3 		$426K Sell
19,119
-89,381
-82% -$2.56M ﹤0.01% 5295
2021
Q2 		$2.46M Buy
+108,500
New +$2.21M ﹤0.01% 4018

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's GLUE Position: Q2 2026 in Review

Goldman Sachs reduced its Monte Rosa Therapeutics (GLUE) stake by 0.33% in Q2 2026, selling an estimated $61.9K and leaving 998,253 shares worth $24.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2453.

Goldman Sachs first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Goldman Sachs held 998,253 shares of Monte Rosa Therapeutics worth $24.2M as of Q2 2026.
  • Goldman Sachs sold 3,274 Monte Rosa Therapeutics shares in Q2 2026, an estimated $61.9K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2453 holding.
  • Goldman Sachs first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.